Risk factors in autism: Thinking outside the brain

Journal of Autoimmunity

Volumn 67, Issue , 2016, Pages 1-7

  Matelski, Lauren ^a,b   Van de Water, Judy ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autism; Gene environment; Immune dysfunction; Maternal factors; Risk

Indexed keywords

ANTIDEPRESSANT AGENT; AUTOANTIBODY; BIOLOGICAL MARKER; GAMMA INTERFERON; HEAVY METAL; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; LYMPHOTOXIN; MATERNAL ANTIBODY; NEUROTRANSMITTER; OXYTOCIN; OZONE; PESTICIDE; POLYBROMINATED DIPHENYL ETHER; POLYCHLORINATED BIPHENYL; PROBIOTIC AGENT; PROTEIN ANTIBODY; SOLVENT; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ABDOMINAL PAIN; AIR POLLUTION; AUTISM; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BACTERIAL INFECTION; BACTEROIDES FRAGILIS; CELIAC DISEASE; COMORBIDITY; CONSTIPATION; COPY NUMBER VARIATION; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIARRHEA; DIET; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FAMILIAL DISEASE; FETUS CIRCULATION; FEVER; FIRST TRIMESTER PREGNANCY; FOLIC ACID DEFICIENCY; FOOD ALLERGY; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MATERNAL AGE; MATERNAL DISEASE; MATERNAL INFECTION; MIXED INFECTION; NONHUMAN; NUTRITIONAL INTOLERANCE; OBESITY; OXIDATIVE STRESS; PASSIVE IMMUNIZATION; PATERNAL AGE; PHARMACOGENOMICS; PHENOTYPE; PRENATAL EXPOSURE; PRENATAL PERIOD; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SECOND TRIMESTER PREGNANCY; STEM CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID DISEASE; VIRUS INFECTION; ZINC DEFICIENCY; ANIMAL; AUTISM SPECTRUM DISORDER; BRAIN; DISEASE PREDISPOSITION; ENVIRONMENT; GENETIC PREDISPOSITION; IMMUNOLOGY; METABOLISM;

ANIMALS; AUTISM SPECTRUM DISORDER; AUTOIMMUNITY; BRAIN; DISEASE SUSCEPTIBILITY; ENVIRONMENT; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PREVALENCE; RISK FACTORS;

EID: 84957436740     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.11.003     Document Type: Review

References (91)

1. Association A.P. DSM-5 Autism Spectrum Disorder Fact Sheet 2013, American Psychiatric Publishing, Accessed 20 October 2015. http://www.dsm5.org/Documents/AutismSpectrumDisorderFactSheet.pdf.
2. McCarthy M. Autism diagnoses in the US rise by 30%, CDC reports. BMJ 2014, 348:g2520.
3. Elsabbagh M., Divan G., Koh Y.J., Kim Y.S., Kauchali S., Marcin C., et al. Global prevalence of autism and other pervasive developmental disorders. Autism Res. Off. J. Int. Soc. Autism Res. 2012, 5:160-179.
4. Volkmar F.R., McPartland J.C. From kanner to DSM-5: autism as an evolving diagnostic concept. Annu. Rev. Clin. Psychol. 2014, 10:193-212.
5. Hansen S.N., Schendel D.E., Parner E.T. Explaining the increase in the prevalence of autism spectrum disorders: the proportion attributable to changes in reporting practices. JAMA Pediatr. 2015, 169:56-62.
6. Lundstrom S., Reichenberg A., Anckarsater H., Lichtenstein P., Gillberg C. Autism phenotype versus registered diagnosis in Swedish children: prevalence trends over 10 years in general population samples. BMJ 2015, 350:h1961.
7. Nevison C.D. A comparison of temporal trends in United States autism prevalence to trends in suspected environmental factors. Environ. Health 2014, 13:73.
8. Hertz-Picciotto I., Delwiche L. The rise in autism and the role of age at diagnosis. Epidemiology 2009, 20:84-90.
9. Area A.S.S.F.B. Autism Rising: a Report on the Increasing Autism Rates in California April 2015.
10. Lai M.-C., Lombardo M.V., Baron-Cohen S. Autism. Lancet 2013, 383(9920):896-910.
11. Karst J.S., Van Hecke A.V. Parent and family impact of autism spectrum disorders: a review and proposed model for intervention evaluation. Clin. Child. Fam. Psychol. Rev. 2012, 15:247-277.
12. Zafeiriou D.I., Ververi A., Dafoulis V., Kalyva E., Vargiami E. Autism spectrum disorders: the quest for genetic syndromes. Am. J. Med. Genet. Part B: Neuropsychiatr. Genet. 2013, 162:327-366.
13. Hallmayer J., Cleveland S., Torres A., Phillips J., Cohen B., Torigoe T., et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch. Gen. Psychiatry 2011, 68:1095-1102.
14. Grabrucker A.M. Environmental factors in autism. Front. psychiatry 2012, 3:118.
15. Croen L.A., Grether J.K., Yoshida C.K., Odouli R., Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch. Gen. Psychiatry 2011, 68:1104-1112.
16. Christensen J., Gronborg T.K., Sorensen M.J., Schendel D., Perner E.T., Pedersen L.H., et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013, 309:1696-1703.
17. Lyall K., Schmidt R.J., Hertz-Picciotto I. The environment in autism spectrum disorders 2013, 203-214.
18. Newschaffer C.J., Croen L.A., Daniels J., Giarelli E., Grether J.K., Levy S.E., et al. The epidemiology of autism spectrum disorders. Annu. Rev. Public Health 2007, 28:235-258.
19. Quaak I., Brouns M.R., Van de Bor M. The dynamics of autism spectrum disorders: how neurotoxic compounds and neurotransmitters interact. Int. J. Environ. Res. Public Health 2013, 10:3384-3408.
20. Ornoy A., Weinstein-Fudim L., Ergaz Z. Prenatal factors associated with autism spectrum disorder (ASD). Reprod. Toxicol. 2015, 56:155-169.
21. Goines P.E., Ashwood P. Cytokine dysregulation in autism spectrum disorders (ASD): possible role of the environment. Neurotoxicol. Teratol. 2013, 36:67-81.
22. Sandin S., Schendel D., Magnusson P., Hultman C., Suren P., Susser E., et al. Autism risk associated with parental age and with increasing difference in age between the parents. Mol. Psychiatry 9 June 2015, advance online publication, [Epub ahead of print]. 10.1038/mp.2015.70.
23. Menezo Y.J., Elder K., Dale B. Link between increased prevalence of autism spectrum disorder syndromes and oxidative stress, DNA methylation, and Imprinting: the impact of the environment. JAMA Pediatr. 2015, 169:1066-1067.
24. Estes M.L., McAllister A.K. Immune mediators in the brain and peripheral tissues in autism spectrum disorder. Nat. Rev. Neurosci. 2015, 16:469-486.
25. Hsiao E.Y. Immune dysregulation in autism spectrum disorder. Int. Rev. Neurobiol. 2013, 113:269-302.
26. Patterson P.H. Maternal infection and immune involvement in autism. Trends Mol. Med. 2011, 17:389-394.
27. Atladottir H.O., Thorsen P., Ostergaard L., Schendel D.E., Lemcke S., Abdallah M., et al. Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. J. Autism Dev. Disord. 2010, 40:1423-1430.
28. Zerbo O., Qian Y., Yoshida C., Grether J.K., Van de Water J., Croen L.A. Maternal infection during pregnancy and autism spectrum disorders. J. Autism Dev. Disord. 2015, 45(12):4015-4025.
29. Zaretsky M.V., Alexander J.M., Byrd W., Bawdon R.E. Transfer of inflammatory cytokines across the placenta. Obstet. Gynecol. 2004, 103:546-550.
30. Garay P.A., McAllister A.K. Novel roles for immune molecules in neural development: implications for neurodevelopmental disorders. Front. Synaptic Neurosci. 2010, 2:136.
31. Deverman B.E., Patterson P.H. Cytokines and CNS development. Neuron 2009, 64:61-78.
32. Goines P.E., Croen L.A., Braunschweig D., Yoshida C.K., Grether J., Hansen R., et al. Increased midgestational IFN-gamma, IL-4 and IL-5 in women bearing a child with autism: A case-control study. Mol. Autism 2011, 2:13.
33. Abdallah M.W., Larsen N., Grove J., Norgaard-Pedersen B., Thorsen P., Mortensen E.L., et al. Amniotic fluid inflammatory cytokines: Potential markers of immunologic dysfunction in autism spectrum disorders. World J. Biol. Psychiatry 2013, 14:528-538.
34. Zerbo O., Iosif A.M., Walker C., Ozonoff S., Hansen R.L., Hertz-Picciotto I. Is maternal influenza or fever during pregnancy associated with autism or developmental delays? Results from the CHARGE (CHildhood Autism Risks from Genetics and Environment) study. J. Autism Dev. Disord. 2013, 43:25-33.
35. S-W Chen, X-S Zhong, L-N Jiang, X-Y Zheng, Y-Q Xiong, S-J Ma, et al. Maternal autoimmune diseases and the risk of autism spectrum disorders in offspring: a systematic review and meta-analysis. Behav. Brain Res. 2016, 296:61-69.
36. Vinet E., Pineau C.A., Clarke A.E., Scott S., Fombonne E., Joseph L., et al. Increased risk of autism spectrum disorders in children born to women with systemic lupus erythematosus, results from a large population-based cohort. Arthritis Rheumatol. 2015, 67(12):3201-3208.
37. Xu G., Jing J., Bowers K., Liu B., Bao W. Maternal diabetes and the risk of autism spectrum disorders in the offspring: a systematic review and meta-analysis. J. Autism Dev. Disord. 2014, 44:766-775.
38. Gesundheit B., Rosenzweig J.P., Naor D., Lerer B., Zachor D.A., Prochazka V., et al. Immunological and autoimmune considerations of autism spectrum disorders. J. Autoimmun. 2013, 44:1-7.
39. Atladottir H.O., Pedersen M.G., Thorsen P., Mortensen P.B., Deleuran B., Eaton W.W., et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics 2009, 124:687-694.
40. Croen L.A., Grether J.K., Yoshida C.K., Odouli R., Van de Water J. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch. Pediatr. Adolesc. Med. 2005, 159:151-157.
41. Keil A., Daniels J.L., Forssen U., Hultman C., Cnattingius S., Soderberg K.C., et al. Parental autoimmune diseases associated with autism spectrum disorders in offspring. Epidemiology 2010, 21:805-808.
42. Kohane I.S., McMurry A., Weber G., MacFadden D., Rappaport L., Kunkel L., et al. The co-morbidity burden of children and young adults with autism spectrum disorders. PLoS One 2012, 7:e33224.
43. Braunschweig D., Van de Water J. Maternal Autoantibodies in Autism. Arch. Neurol. 2012, 69:693-699.
44. Singer H.S., Morris C.M., Gause C.D., Gillin P.K., Crawford S., Zimmerman A.W. Antibodies against fetal brain in sera of mothers with autistic children. J. Neuroimmunol. 2008, 194:165-172.
45. Brimberg L., Sadiq A., Gregersen P.K., Diamond B. Brain-reactive IgG correlates with autoimmunity in mothers of a child with an autism spectrum disorder. Mol. Psychiatry 2013, 18:1171-1177.
46. Braunschweig D., Krakowiak P., Duncanson P., Boyce R., Hansen R.L., Ashwood P., et al. Autism-specific maternal autoantibodies recognize critical proteins in developing brain. Transl. psychiatry 2013, 3:e277.
47. Enstrom A.M., Onore C.E., Van de Water J.A., Ashwood P. Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav. Immun. 2010, 24:64-71.
48. Ashwood P., Krakowiak P., Hertz-Picciotto I., Hansen R., Pessah I.N., Van de Water J. Altered T cell responses in children with autism. Brain Behav. Immun. 2011, 25:840-849.
49. Ashwood P., Corbett B.A., Kantor A., Schulman H., Van de Water J., Amaral D.G. In search of cellular immunophenotypes in the blood of children with autism. PLoS One 2011, 6:e19299.
50. Breece E., Paciotti B., Nordahl C.W., Ozonoff S., Van de Water J.A., Rogers S.J., et al. Myeloid dendritic cells frequencies are increased in children with autism spectrum disorder and associated with amygdala volume and repetitive behaviors. Brain Behav. Immun. 2013, 31:69-75.
51. Heuer L.S., Rose M., Ashwood P., Van de Water J. Decreased levels of total immunoglobulin in children with autism are not a result of B cell dysfunction. J. Neuroimmunol. 2012, 251:94-102.
52. Ashwood P., Krakowiak P., Hertz-Picciotto I., Hansen R., Pessah I., Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav. Immun. 2011, 25:40-45.
53. Ashwood P., Krakowiak P., Hertz-Picciotto I., Hansen R., Pessah I.N., Van de Water J. Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders. J. Neuroimmunol. 2011, 232:196-199.
54. Ricci S., Businaro R., Ippoliti F., Lo Vasco V.R., Massoni F., Onofri E., et al. Altered cytokine and BDNF levels in autism spectrum disorder. Neurotox. Res. 2013, 24:491-501.
55. Li X., Chauhan A., Sheikh A.M., Patil S., Chauhan V., Li X.M., et al. Elevated immune response in the brain of autistic patients. J. Neuroimmunol. 2009, 207:111-116.
56. Depino A.M. Peripheral and central inflammation in autism spectrum disorders. Mol. Cell Neurosci. 2013, 53:69-76.
57. Masi A., Quintana D.S., Glozier N., Lloyd A.R., Hickie I.B., Guastella A.J. Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis. Mol. Psychiatry 2014, 20:440-446.
58. Voineagu I., Wang X., Johnston P., Lowe J.K., Tian Y., Horvath S., et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 2011, 474:380-384.
59. Gupta S., Ellis S.E., Ashar F.N., Moes A., Bader J.S., Zhan J., et al. Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. Nat. Commun. 2014, 5:5748.
60. Pramparo T., Pierce K., Lombardo M.V., Carter Barnes C., Marinero S., Ahrens-Barbeau C., et al. Prediction of autism by translation and immune/inflammation coexpressed genes in toddlers from pediatric community practices. JAMA Psychiatry 2015, 72:386-394.
61. Rodriguez J.I., Kern J.K. Evidence of microglial activation in autism and its possible role in brain underconnectivity. Neuron Glia Biol. 2011, 7:205-213.
62. Mayer E.A., Tillisch K., Gupta A. Gut/brain axis and the microbiota. J. Clin. Invest 2015, 125:926-938.
63. Wang Y., Kasper L.H. The role of microbiome in central nervous system disorders. Brain Behav. Immun. 2014, 38:1-12.
64. Kral T.V., Eriksen W.T., Souders M.C., Pinto-Martin J.A. Eating behaviors, diet quality, and gastrointestinal symptoms in children with autism spectrum disorders: a brief review. J. Pediatr. Nurs. 2013, 28:548-556.
65. Bresnahan M., Hornig M., Schultz A.F., Gunnes N., Hirtz D., Lie K.K., et al. Association of maternal report of infant and toddler gastrointestinal symptoms with autism: evidence from a prospective birth cohort. JAMA Psychiatry 2015, 72:466-474.
66. Rosenfeld C.S. Microbiome disturbances and autism spectrum disorders. Drug Metab. Dispos. 2015, 43:1557-1571.
67. Mayer E.A., Padua D., Tillisch K. Altered brain-gut axis in autism: comorbidity or causative mechanisms?. Bioessays 2014, 36:933-939.
68. Kim Y.S., Leventhal B.L. Genetic epidemiology and insights into interactive genetic and environmental effects in autism spectrum disorders. Biol. Psychiatry 2015, 77:66-74.
69. Stamou M., Streifel K.M., Goines P.E., Lein P.J. Neuronal connectivity as a convergent target of gene x environment interactions that confer risk for autism spectrum disorders. Neurotoxicol. Teratol. 2013, 36:3-16.
70. Mazina V., Gerdts J., Trinh S., Ankenman K., Ward T., Dennis M.Y., et al. Epigenetics of autism-related impairment: copy number variation and maternal infection. J. Dev. Behav. Pediatr. 2015, 36:61-67.
71. Servadio M., Vanderschuren L.J., Trezza V. Modeling autism-relevant behavioral phenotypes in rats and mice: Do 'autistic' rodents exist?. Behav. Pharmacol. 2015, 26:522-540.
72. Boksa P. Effects of prenatal infection on brain development and behavior: a review of findings from animal models. Brain Behav. Immun. 2010, 24:881-897.
73. Smith S.E., Li J., Garbett K., Mirnics K., Patterson P.H. Maternal immune activation alters fetal brain development through interleukin-6. J. Neurosci. 2007, 27:10695-10702.
74. Bauman M.D., Iosif A.M., Smith S.E., Bregere C., Amaral D.G., Patterson P.H. Activation of the maternal immune system during pregnancy alters behavioral development of rhesus monkey offspring. Biol. Psychiatry 2014, 75:332-341.
75. Schwartzer J.J., Careaga M., Onore C.E., Rushakoff J.A., Berman R.F., Ashwood P. Maternal immune activation and strain specific interactions in the development of autism-like behaviors in mice. Transl. psychiatry 2013, 3:e240.
76. Garbett K.A., Hsiao E.Y., Kalman S., Patterson P.H., Mirnics K. Effects of maternal immune activation on gene expression patterns in the fetal brain. Transl. Psychiatry 2012, 2:e98.
77. Hsiao E.Y., McBride S.W., Hsien S., Sharon G., Hyde E.R., McCue T., et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 2013, 155:1451-1463.
78. de Theije C.G., Wopereis H., Ramadan M., van Eijndthoven T., Lambert J., Knol J., et al. Altered gut microbiota and activity in a murine model of autism spectrum disorders. Brain Behav. Immun. 2014, 37:197-206.
79. Braunschweig D., Golub M.S., Koenig C.M., Qi L., Pessah I.N., Van de Water J., et al. Maternal autism-associated IgG antibodies delay development and produce anxiety in a mouse gestational transfer model. J. Neuroimmunol. 2012, 252:56-65.
80. Singer H.S., Morris C., Gause C., Pollard M., Zimmerman A.W., Pletnikov M. Prenatal exposure to antibodies from mothers of children with autism produces neurobehavioral alterations: a pregnant dam mouse model. J. Neuroimmunol. 2009, 211:39-48.
81. Bauman M.D., Iosif A.M., Ashwood P., Braunschweig D., Lee A., Schumann C.M., et al. Maternal antibodies from mothers of children with autism alter brain growth and social behavior development in the rhesus monkey. Transl. psychiatry 2013, 3:e278.
82. Martinez-Cerdeno V., Camacho J., Fox E., Miller E., Ariza J., Kienzle D., et al. Prenatal exposure to autism-specific maternal autoantibodies alters proliferation of cortical neural precursor cells, enlarges brain, and increases neuronal size in adult animals. Cereb. Cortex 2016, 26(1):374-383.
83. Acab A., Muotri A.R. The use of induced pluripotent stem cell technology to advance autism research and treatment. Neurotherapeutics 2015, 12:534-545.
84. Mariani J., Coppola G., Zhang P., Abyzov A., Provini L., Tomasini L., et al. FOXG1-dependent dysregulation of GABA/Glutamate Neuron Differentiation in Autism Spectrum Disorders. Cell 2015, 162:375-390.
85. DeRosa B.A., Van Baaren J.M., Dubey G.K., Lee J.M., Cuccaro M.L., Vance J.M., et al. Derivation of autism spectrum disorder-specific induced pluripotent stem cells from peripheral blood mononuclear cells. Neurosci. Lett. 2012, 516:9-14.
86. Kim D.S., Ross P.J., Zaslavsky K., Ellis J. Optimizing neuronal differentiation from induced pluripotent stem cells to model ASD. Front. Cell Neurosci. 2014, 8:109.
87. Mari-Bauset S., Zazpe I., Mari-Sanchis A., Llopis-Gonzalez A., Morales-Suarez-Varela M. Evidence of the gluten-free and casein-free diet in autism spectrum disorders: a systematic review. J. Child. Neurol. 2014, 29:1718-1727.
88. Lange K.W., Hauser J., Reissmann A. Gluten-free and casein-free diets in the therapy of autism. Curr. Opin. Clin. Nutr. Metab. Care 2015, 18(6):572-575.
89. McDougle C.J., Landino S.M., Vahabzadeh A., O'Rourke J., Zurcher N.R., Finger B.C., et al. Toward an immune-mediated subtype of autism spectrum disorder. Brain Res. 2015, 1617:72-92.
90. Bowers K., Lin P.I., Erickson C. Pharmacogenomic medicine in autism: challenges and opportunities. Paediatr. Drugs 2015, 17:115-124.
91. Adam J. Guastella, Ian B. Hickie, Oxytocin treatment, circuitry and autism: a critical review of the literature placing oxytocin into the autism context, Biol. Psychiatry, http://dx.doi.org/10.1016/j.biopsych.2015.06.028, (in press).